MustGrow Biologics Corp.

MustGrow Biologics Corp.

MGROF
MustGrow Biologics Corp.US flagOther OTC
0.23
USD
-0.03
- -
14.74MMarket Cap
MustGrow Biologics Corp.
MGROF
(Other OTC)

Recent

price

0.23

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
0.09
0.01
0.15
0.08
Revenue per Share
- -
-0.01
-0.08
-0.06
-0.09
-0.07
-0.11
-0.01
-0.09
-0.13
-0.12
Basic EPS, GAAP
- -
-0.01
-0.04
-0.05
-0.07
-0.06
-0.07
-0.01
-0.07
-0.09
-0.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.07
-0.06
0.05
- -
0.14
0.03
0.04
-0.05
-0.12
-0.12
Book Value per Share
- -
-0.05
-0.02
0.12
0.06
0.19
0.11
0.11
0.03
0.02
0.02
Tangible Book Value per Share
25
25
25
25
37
44
49
50
52
54
56
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
5
- -
8
5
Sales/Revenue/Turnover
- -
-13,662.61
-92,656.85
- -
- -
-23,408.97
-87,746.92
-17.08
-1,284.91
-75.45
-122.4
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
-2
-2
-3
-3
-6
-1
-5
-7
-7
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-9,398.86
-94,668.85
- -
- -
-23,808.18
-85,905.87
-14.37
-1,228.27
-87.58
-150.77
Profit Margin (%)
- -
-1
- -
3
3
9
6
6
2
1
1
Working Capital
- -
1
1
- -
1
- -
- -
- -
- -
- -
- -
LT Debt
- -
-1
- -
3
2
8
5
6
2
1
1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-475.73
-99.48
-150.14
-42.3
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
59
59
63
Market Capitalization
33
33
31

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6
3
3
Cash, Cash Equivalents & STI
3
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
2
2
- -
Total Current Liabilities
3
2
2
Payables & Accruals
3
2
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
22.22%
-60.03%
Free Cash Flow
- -
218.59%
41.37%
Net Income, GAAP
- -
131.41%
48.46%
Sales/Revenue/Turnover
- -
15,002.91%
1,981.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
3
1
1
8
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.03
- -
-0.09
2025
-0.03
-0.02
-0.04
- -
-0.13
2026
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
MustGrow Biologics Corp. (TSXV:MGRO; OTCQB:MGROF), founded in 2014 and headquartered in Saskatoon, Saskatchewan, Canada, develops and commercializes innovative biological and regenerative agriculture solutions derived from mustard seed to replace synthetic chemicals and fertilizers; its proprietary TerraMG platform offers soil biocontrol products treating soil-borne pests, diseases, nematodes and weeds in crops including fruits and vegetables, preplant soil biofumigants, bioherbicides, postharvest potato sprout suppression and pathogen control technologies; TerraSante provides organic biofertility through vegetable proteins and nutrients that stimulate beneficial microbial activity and soil health; through its NexusBioAg division, the company distributes third-party crop nutrition solutions such as micronutrients, nitrogen stabilizers, biostimulants, adjuvants and folars primarily in North America. MustGrow holds approximately 112 issued and pending patents supporting its platform across agriculture, home and garden, storage preservation, and potential animal and human health applications, while targeting organic and sustainable farming markets globally amid regulatory restrictions on synthetic agchems. The company maintains an exclusive commercial license agreement with Bayer AG, signed in December 2023, to commercialize preplant soil biocontrol technologies in Europe, the Middle East and Africa; it completed the acquisition of NexusBioAg assets from Univar Solutions Canada Ltd. on December 31, 2024 for approximately C$1.7 million in deferred cash plus 2025-2026 earn-outs to integrate sales, marketing and distribution capabilities; recent advancements include California organic registration for TerraSante in May 2024 enabling initial U.S. sales ramp-up in 2025-2026, alongside securing a C$2.0 million line of credit with CIBC guaranteed by EDC in September 2025 and reporting record Q3-2025 results.

Company News

APIChatGPT
  • MustGrow Biologics Corp. Announces Results of Shareholder Meeting

  • MustGrow Closes $3.7 Million Non-Brokered LIFE Offering

  • MustGrow Increases Non-Brokered LIFE Offering to Approximately $3.7 Million

  • MustGrow Announces First Quarter 2026 Financial Results

  • MustGrow Announces Non-Brokered LIFE Offering of Approximately $2 Million

  • MustGrow Biologics receives TerraSante approvals in Texas, Utah and Montana

  • MustGrow Receives Texas, Utah, and Montana Registrations for TerraSante(TM) Biofertility Product

  • Huawei Technologies unveils new design chip strategy amid intensifying global competition

  • MustGrow Announces Market Awareness Services and Investor Relations Agreements

  • Rivian beats earnings estimates amid R2 production ramp

  • Sandisk could blow past its own guidance as NAND pricing hits triple digits

  • MustGrow Biologics reports jump in revenue as TerraSante US sales drive growth

  • MustGrow Announces 2025 Financial Results

  • MustGrow wins Georgia approval for TerraSante biofertility product

  • MustGrow Receives Georgia Registration for TerraSante(TM) Biofertility Product

  • At 95, Warren Buffett refuses to stop: The curious case of the never-retired billionaire

  • Carvana surges as Jefferies flags strong unit growth, pricing momentum

  • MustGrow pivots to US TerraSante growth

  • Nvidia’s China question is back and the clock is ticking

  • Amazon expands access to digital assistant Alexa+